Syngene International Announces Extension Of Collaboration With Amgen

• Contract extended until 2026
• Under the extended contract, the dedicated R&D center, ‘Syngene Amgen Research and Development Center’ (SARC), will continue to conduct drug discovery and development projects as part of Amgen’s global R&D program.
• Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects.

Bangalore: Syngene International, an integrated research, development and manufacturing services company, today announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc, one of the world’s leading biotechnology companies. The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory which will enable R&D project acceleration.

Jonathan Hunt, CEO and Managing Director, Syngene International Ltd., said, "While SARC was established in 2016, our collaboration with Amgen dates back to 2012. During this time, we have partnered on research and development to address some of the most serious diseases in the world. We have progressively expanded our areas of collaboration, co-authored research papers on novel science and supported the advancement of multiple development projects, while adhering to global standards of quality and safety. We are proud to have played a role in advancing molecules that are making a difference to patients around the world today. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new state-of-the-art facility to the collaboration.”

“Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials,” said Margaret Chu-Moyer, Ph.D., Vice President of Research and Head of Chemistry, Characterization & Technology at Amgen. “We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.”

SARC was established in 2016 and Syngene announced expansion of the original dedicated center in 2017. It currently consists of 60,000 sq. ft. of floor space and a dedicated team of multi-disciplinary Syngene scientists who work closely with Amgen researchers around the world on the discovery and development of innovative medicines.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA. For more details, visit www.syngeneintl.com

Contact details